Patents by Inventor Lino J. Valdez

Lino J. Valdez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11413274
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 16, 2022
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelis Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Publication number: 20210046045
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 18, 2021
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelis Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 10736875
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: August 11, 2020
    Assignee: LIGAND PHARMACEUTICALS, INC.
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelis Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Publication number: 20180369197
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Application
    Filed: September 10, 2018
    Publication date: December 27, 2018
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelius Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 10111859
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: October 30, 2018
    Assignee: LIGAND PHARMACEUTICALS, INC.
    Inventors: Lin Zhi, Andrew R. Hudson, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelius Arjan van Oeveren, Lino J. Valdez
  • Patent number: 9622991
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: April 18, 2017
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Bijan Pedram, Yixing Shen, Lino J. Valdez, Jillian Basinger, Virginia Heather Sharron Grant, Jason C. Pickens
  • Publication number: 20160374989
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Application
    Filed: August 25, 2016
    Publication date: December 29, 2016
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelius Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 9492430
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: November 15, 2016
    Assignee: Ligand Pharmaceuticals, Incorporated
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, C. Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 9144557
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: September 29, 2015
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Lin Zhi, Andrew R Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Bijan Pedram, Yixing Shen, Lino J. Valdez, Jillian Basinger, Virginia Heather Sharron Grant, Jason C. Pickens
  • Publication number: 20150252043
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Application
    Filed: May 15, 2015
    Publication date: September 10, 2015
    Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Bijan Pedram, Yixing Shen, Lino J. Valdez, Jillian Basinger, Virginia Heather Sharron Grant, Jason C. Pickens
  • Publication number: 20140296292
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 2, 2014
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, C. Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 8680150
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: March 25, 2014
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Jason C. Pickens, Yixing Shen, Catalina Cuervo, Lino J. Valdez, Jillian Basinger, Virgina H. Grant
  • Publication number: 20120295904
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Application
    Filed: October 12, 2010
    Publication date: November 22, 2012
    Applicant: LIGAND PHARMACEUTICALS INC.
    Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Bijan Pedram, Yixing Shen, Lino J. Valdez, Jillian Basinger, Virginia Heather Sharron Grant, Jason C. Pickens
  • Publication number: 20110003851
    Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
    Type: Application
    Filed: May 6, 2010
    Publication date: January 6, 2011
    Applicant: Ligand Pharmaceuticals, Inc.
    Inventors: Lin Zhi, Andrew R. Hudson, Cornelis A. Van Oeveren, Steven L. Roach, Jason C. Pickens, Yixing Shen, Catalina Cuervo, Lino J. Valdez, Jillian Basinger, Virgina H. Grant